(BPT) - Lilly Rockwell’s earliest memories are having headaches so severe she would vomit. Since her mother suffers from migraine, they assumed that’s what Lilly had too. Lilly and her family sought advice from doctors to alleviate her symptoms, but without success, so she continued to struggle with migraine into her adult life. “As my migraine disease progressed and I got older, I was constantly worried about having an attack and how it might impact time with my family and friends, and my profession as a real estate agent. I need to be focused every day to help my clients find their dream home. I cannot be sidelined for days with a migraine.”
Migraine is a debilitating neurologic disease that affects nearly 40 million Americans with women three times more likely to suffer than men. A recent survey conducted by the National Headache Foundation found that migraine has a broad and negative impact on people’s lives, affecting their energy level, mental clarity, productivity, personal relationships, and professional success. In fact, more than half of people with migraine are not satisfied with their ability to control the disease.
Clinical Trial Brings New Outlook on Life
After talking with her mom who was participating in a clinical trial evaluating the oral calcitonin gene-related peptide (CGRP) receptor antagonist, Nurtec® ODT (rimegepant), for the preventive treatment of migraine, Lilly decided to enroll herself. This was the first time she was able to experience more migraine-free days. “Using Nurtec ODT, my career and social life flourished,” said Lilly. She describes her experience during the trial as eye-opening where she was able to enjoy the little things in life.
Breakthrough Dual Therapy Proven to Treat and Prevent Migraine
In May 2021, the U.S. Food and Drug Administration (FDA) approved Nurtec ODT (rimegepant) for the preventive treatment of episodic migraine in adults. This new approval makes Nurtec ODT the first and only medication approved by the FDA to treat and prevent migraine attacks. A single dose of Nurtec ODT can bring fast pain relief that lasts up to 48 hours for many patients. Nurtec ODT is proven to start dissolving pain in an hour and can also reduce monthly migraine days by at least half compared to placebo.
Available by prescription, Nurtec ODT gives people with migraine like Lilly a more complete, flexible treatment plan to help control their migraine disease. For more information, visit nurtec.com.
Indication
NURTEC ODT orally disintegrating tablets is a prescription medicine that is used to treat migraine in adults. It is for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine. It is not known if NURTEC ODT is safe and effective in children.
Important Safety Information
Do not take NURTEC ODT if you are allergic to NURTEC ODT (rimegepant) or any of its ingredients.
Before you take NURTEC ODT, tell your healthcare provider (HCP) about all your medical conditions, including if you:
- have liver problems,
- have kidney problems,
- are pregnant or plan to become pregnant,
- breastfeeding or plan to breastfeed.
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
NURTEC ODT may cause serious side effects including allergic reactions, including trouble breathing and rash. This can happen days after you take NURTEC ODT. Call your HCP or get emergency help right away if you have swelling of the face, mouth, tongue, or throat or trouble breathing. This occurred in less than 1% of patients treated with NURTEC ODT.
The most common side effects of NURTEC ODT were nausea (2.7%) and stomach pain/indigestion (2.4%). These are not the only possible side effects of NURTEC ODT. Tell your HCP if you have any side effects.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Biohaven at 1-833-4NURTEC.
Please click here for full Prescribing Information and Patient Information.
US-RIMODT-2100409 05/13/2021
